The Governors of the University of Calgary

Debate over labeling some prostate cancers as 'cancer' continues. Delayed lung cancer treatment linked to worse survival. FDA approval process scrutinized after drug withdrawals. FDA expands indications for asciminib and methotrexate. Burn scars linked to aggressive skin cancer. Phase II/III trial of E-selectin antagonist fails to meet primary endpoint. Survey reveals challenges in cancer survivorship. Diabetes drug metformin's anticancer potential under scrutiny. Doctor sentenced for Medicare fraud. Physician charged with illegal cancer drug scheme. AI reveals risk status misclassification in prostate cancer trials. Biden admin announces $6M in grants for Cancer Moonshot program.

J&J and Eli Lilly revealed efficacy of their IL-23 inhibitors, Tremfya and Omvoh, in treating Crohn’s disease, with both drugs showing significant clinical and endoscopic remission rates in Phase III trials. Both companies aim for FDA approval, with Tremfya already approved for UC, plaque psoriasis, and psoriatic arthritis, while Omvoh is superior to Stelara in treating Crohn's disease. GlobalData predicts Tremfya sales to reach $8.4bn by 2030, surpassing Omvoh's projected $867m.

J&J and Eli Lilly revealed efficacy data for their IL-23 inhibitors, Tremfya and Omvoh, in treating Crohn’s disease, with both drugs aiming for FDA approval. Tremfya showed 60-66.1% clinical remission rates at 48 weeks, while Omvoh achieved 81% clinical and 82% endoscopic remission after two years. GlobalData forecasts Tremfya sales to reach $8.4bn by 2030, surpassing Omvoh's projected $867m.

Study estimates HCC incidence in SLD patients, finding higher rates in males, older individuals, those with cirrhosis, DM, CKD, CVD, and non-liver cancer. Incidence rises with age, male sex, cirrhosis, and DM, peaking at 19.06/1,000 PY in males >70 with cirrhosis and DM. Lowest risk is in noncirrhotic, nondiabetic patients <40. Results suggest tailored surveillance strategies based on multiple risk factors.

A study published in the journal Addiction suggests that weight-loss medications like Ozempic could reduce overdose and alcohol intoxication risks in people with substance use disorders. Researchers found that those taking these drugs had a 40% lower chance of overdosing and a 50% lower chance of getting drunk. Experts see potential for these medications to also reduce stigma associated with substance use, though they are not yet FDA-approved for this purpose.

Tulisokibart maintained clinical and endoscopic improvements in IBD patients through week 50 in phase II trial extensions, with 48% of ulcerative colitis patients and 56% of Crohn's disease patients achieving clinical remission. The drug was well-tolerated with no identified safety signals.

The Cumming School of Medicine aims to transform health-care education through precision equity, led by the Health Equity and Systems Transformation portfolio. This approach, spearheaded by Dr. Kannin Osei-Tutu and others, involves tailored interventions to address specific biases and inequities within the medical school community, with the goal of fostering inclusive practices and driving structural reform. The strategy includes needs assessments, impact studies, and a toolkit to support EDIA work, aiming to create a more inclusive and resilient academic environment that will influence future health-care practices.

Authors and affiliations: Mohamed Ben-Eltriki, Aisha Rafiq, Arun Paul, Lauren E Kelly, Devashree Prabhu, Michael O. S. Afolabi, Robert Baslhaw, Salaheddin M Mahmud, Christine J Neilson, Thierry Lacaze-Masmonteil, Susan Marlin, Martin Offringa, Nancy Butcher, Anna Heath, Michelle Driedger. Contributions: MBE, AR, AP, DP, MO.S. A, CJ N, RB, SMM, TLM, SM, MO, NB, AH, MD, LEK. Correspondence: Mohamed Ben-Eltriki, Lauren E Kelly.

Registration is open for the Great Plains IDeA-CTR’s 2024 Annual Scientific Meeting on Oct. 21 at the University of Nebraska at Omaha’s Scott Conference Center. The free event, themed “Leveraging AI and Innovative Study Designs to Transform Healthcare and Improve Patient Outcomes,” offers up to five continuing education credits and features speakers on AI in healthcare, NIH funding, and health data management. The CTR Superstar Competition will award $35,000 to a promising scholar. Register soon due to limited seating.